uPA Antibodies

Santa Cruz Biotechnology features a diverse variety of uPA monoclonal antibodies for investigating urokinase-type plasminogen activator (uPA) in various biological processes. uPA Antibodies targeting uPA are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Urokinase-type plasminogen activator is a serine protease that plays a critical role in the fibrinolytic system, facilitating the conversion of plasminogen to plasmin, which is essential for extracellular matrix remodeling and tissue repair. uPA is involved in various physiological and pathological processes, including cell migration, invasion, and tumor progression, making it a significant target for cancer research. Understanding the function of uPA can provide insights into its potential as a biomarker and therapeutic target in various diseases. Research has shown that uPA expression levels correlate with cancer progression and metastasis in multiple tumor types. Monitoring uPA activity helps evaluate treatment effectiveness and disease progression. Santa Cruz Biotechnology monoclonal antibodies targeting uPA enable researchers to advance scientific understanding of cancer biology and therapeutic development.